ALLO

Allogene Therapeutics, Inc. Common Stock

1.75

USD

ALLO Earnings Reports

Positive Surprise Ratio

ALLO beat 26 of 29 last estimates.

90%

Next Report

Date of Next Report

Mar 11, 2026

Estimate for Q4 25 (Revenue/ EPS)

-$0.21

Implied change from Q3 25 (Revenue/ EPS)

+10.53%

Implied change from Q4 24 (Revenue/ EPS)

-25.00%

Allogene Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, ALLO reported earnings of -0.19 USD per share (EPS) for Q3 25, beating the estimate of -0.22 USD, resulting in a 16.56% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +12.38% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 16 analysts forecast an EPS of -0.21 USD, with revenue projected to reach -- USD, implying an increase of 10.53% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Nurix Therapeutics, Inc. Common stock

Report Date

Jan 28, 2026 For Q4 25

Estimate

-$0.88

Actual

-$0.82

Surprise

+7.66%

Regeneron Pharmaceuticals Inc

Report Date

Jan 30, 2026 For Q4 25

Estimate

$10.84

Actual

$11.44

Surprise

+5.52%

Twist Bioscience Corporation Common Stock

Report Date

Feb 02, 2026 For Q1 26

Estimate

-$0.43

Actual

-$0.50

Surprise

-14.00%

FAQ

What were Allogene Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Allogene Therapeutics, Inc. Common Stock reported EPS of -$0.19, beating estimates by 16.56%, and revenue of $0.00, 0% as expectations.

How did the market react to Allogene Therapeutics, Inc. Common Stock's Q3 2025 earnings?

The stock price moved up 12.38%, changed from $1.05 before the earnings release to $1.18 the day after.

When is Allogene Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 11, 2026.

What are the forecasts for Allogene Therapeutics, Inc. Common Stock's next earnings report?

Based on 16 analysts, Allogene Therapeutics, Inc. Common Stock is expected to report EPS of -$0.21 and revenue of -- for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.